Drug Trial Radar · NCT00247962
Study Evaluating Etanercept and Sulphasalazine in Ankylosing Spondylitis
Last checked: Nov 20, 2026Latest source record: Nov 8, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
566
Actual
Start
Dec 2005
Primary completion
Feb 2008
Study completion Feb 2008
Sponsor
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 2, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy of etanercept and sulphasalazine in the treatment of Ankylosing Spondylitis.
Conditions
- Ankylosing Spondylitis
Interventions
etanerceptDrug
50 mg
sulphasalazine (SSZ)Drug
Sulphasalazine: The target dose for SSZ is 1.5 g (3 tablets) twice daily orally. Subject start the oral TA at 0.5 g daily for the first week and increase by 0.5 g every week until a daily dose of 3 g. Is achieved by the start of study week 5 of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients Achieving Assessment in Ankylosing Spondylitis (ASAS 20)Time frame: 16 weeks
Locations
83 sites in 18 countries. Site status is shown where the registry gives one.
Site not named
Heidelberg West, Victoria, Australia
Site not named
Shenton Park, Western Australia, Australia
Site not named
Innsbruck, Austria
Site not named
Klagenfurt, Austria
Site not named
Linz, Austria
Site not named
Beijing, China
Site not named
Shanghai, China
Site not named
Ostrava, Czechia
Site not named
Prague, Czechia
Site not named
Frederiksberg, Denmark
Site not named
Kolding, Denmark
Site not named
Odense, Denmark
Site not named
Vejle, Denmark
Site not named
Helsinki, Finland
Site not named
Kuopio, Finland
Site not named
Tampere, Finland
Site not named
Amiens, France
Site not named
Bordeaux, France
Site not named
Boulogne-Billancourt, France
Site not named
Créteil, France
Site not named
Marseille, France
Site not named
Nantes, France
Site not named
Orléans, France
Site not named
Pierre Mendès, France
Site not named
Toulouse, France
Site not named
Berlin, Germany
Site not named
Berlin, Germany
Site not named
Erlangen, Germany
Site not named
Gommern, Germany
Site not named
Hamburg, Germany
Site not named
Herne, Germany
Site not named
Heubnerweg, Germany
Site not named
Hildesheim, Germany
Site not named
München, Germany
Site not named
Pirna, Germany
Site not named
Ratingen, Germany
Site not named
Wiesbaden, Germany
Site not named
Wiesbaden, Germany
Site not named
Debrecen, Hungary
Site not named
Győr, Hungary
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.